403 results about "Senescence" patented technology

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein. In various embodiments, the disclosure also provides for the treatment of aging, senescence, fibrosis, metabolic diseases, cardiovascular diseases, endocrine-related disorders, genetic diseases, cancer, infections, immune diseases, and the like using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein. Methods of replacing an adaptation of therapy or combinations thereof with hormones, growth factors and / or proteins, as well as methods of identifying the agents.

The invention discloses a ginseng extract rich in rare saponins and preparation and anti-aging application thereof, and belongs to the technical field of oral beauty and skin care products, the ginseng extract is obtained by fermentation treatment of ginseng powder through phytobacterium plantarum, and the preservation number of the phytobacterium plantarum is GDMCC No.64374. The ginseng extract rich in rare saponin is fermented by specific plant lactobacillus, ginsenoside is efficiently converted into CK and F1, various natural plant components such as ginseng polysaccharide are reserved, and a specific synergistic effect is generated. Through verification, the prepared ginseng extract is high in bioavailability, can more effectively inhibit cell inflammation, and can more effectively recover the mitochondrial function of senescent cells and inhibit cell senescence. The preparation method provided by the invention is high in operability and easy to standardize and intellectualize. Compared with a traditional extraction and purification method, the adopted fermentation method is more environmentally friendly and efficient, and large-scale production can be achieved in industrial production.

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein, such as a cytokine. In various embodiments, the disclosure also provides methods of treating inflammation, aging, senescence, fibrosis, autoimmunity, cancer, infection, and / or immunological disease using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein, as well as methods of identifying the agents.

The invention discloses sturgeon ovary active peptide with ovary aging resistance and a preparation method of the sturgeon ovary active peptide. According to the invention, sturgeon ovary is taken as a raw material, and peptide with the highest ovarian aging resistance activity is selected from different enzymolysis combinations through an in-vitro anti-oxidation test and an ovarian granular cell and caenorhabditis elegans test; three sturgeon ovary active peptide sequences with ovary senescence resistance activity are screened by virtue of bioinformatics technologies such as mass spectrum identification, molecular docking and the like, and the amino acid sequences of the sturgeon ovary active peptide sequences are Phe-Met-Ile (FMI), Phe-Asp-Pro-Phe (FDPF) and Ser-Trp-Pro-Trp-Gln (SWPWQ). The sturgeon ovarian peptide prepared by the method not only has remarkable anti-premature ovarian failure activity and successfully solves the problem of high-valued utilization of sturgeon byproducts, but also can be used as a natural and efficient functional factor, is widely applied to functional products in the related fields of health care products, cosmetics, medicines and the like, and has a wide application prospect. And the method shows extremely wide market application prospects and huge economic values.

The invention discloses a gene RhNADP-LIKE for regulating and controlling Chinese rose flower aging, and particularly relates to the technical field of molecular biology and horticultural plant physiology. According to the invention, bottle insertion life phenotype data of 358 parts of core germplasm of tetraploid Chinese rose is screened through genome-wide association analysis (GWAS), and the gene RhNADP-LIKE significantly associated with senescence is identified. The gene accelerates the aging process of petals by regulating the accumulation of reactive oxygen species (ROS). After RhNADP-LIKE expression is inhibited by using a virus-induced gene silencing (VIGS) technology, the blooming period of rosa chinensis flowers is prolonged by about 2 days, and the ROS level is remarkably reduced. The invention provides a molecular target for prolonging the vase life of the Chinese rose, can be applied to gene editing breeding or development of an environment-friendly preservative, reduces the dependence of chemical agents, and improves the economic benefit and sustainable development potential of the cut flower industry.

The invention belongs to the field of microorganisms, and particularly relates to application of lactobacillus paracasei L9 in preparation of a preparation for improving pulmonary fibrosis of an aged mouse. According to the lactobacillus paracasei L9 disclosed by the invention, the synthesis of I-type collagen is reduced by regulating and controlling gene expression, so that pulmonary fibrosis is relieved; meanwhile, the L9 improves the content of propionic acid and butyric acid in intestinal tracts and serum by regulating the abundance of SCFA-producing microbial flora in the intestinal tracts, so that pulmonary fibrosis is inhibited, and the L9 is a potential ideal preparation for improving or treating aging-related pulmonary fibrosis.

The invention discloses a senescent cell recognition system and method based on mitochondrial morphology. The system is a classification network, and the input data of the system is a distribution image of mitochondria in subcellular level cells, the distribution image of mitochondria in cells, the shape and / or number of mitochondria distributed at different positions in a three-dimensional structure for displaying cells, and preferably the shape and number of mitochondria distributed at different positions in the three-dimensional structure for displaying cells. According to the senescence cell recognition system based on the mitochondrial morphology, the senescence cells jointly show mitochondrial morphological changes including mitochondrial distribution, mitochondrial shapes and mitochondrial number changes, the senescence cell recognition method is easy to conduct through computer vision, good robustness is achieved, and the senescence cell recognition system based on the mitochondrial morphology is suitable for being applied to senescence cell recognition. Compared with other senescence cell identification methods based on cell nucleus morphological characteristics, the senescence cell identification method based on the general characteristics of the senescence cells has good universality for different cell types.

Provided is a mammalian-derived cell model that can be used in anti-aging drugs. The mammalian-derived extraembryonic trophoblast cell model is an early mammalian-derived extraembryonic stage. A change model and an aging evaluation index system for differentiating the cells into the extraembryonic trophoblast cells / organoids can be used for various anti-aging researches and target detection, anti-aging drug detection, screening and identification, research on innovative drugs / natural products, and development of chemicals and / or health foods and additives. Screening and identifying many resistances is helpful. Candidate targets of aging may be further mechanically and functionally validated for future therapeutic use. The screening of anti-aging drugs or natural products will produce huge economic and social benefits.

The invention discloses a traditional Chinese medicine composition for repairing and / or activating residual ovarian functions of an aging ovary, and a preparation method and application thereof, and relates to the technical field of biology. The traditional Chinese medicine composition is prepared from the following components: radix astragali, radix angelicae sinensis, radix ophiopogonis, radix polygonati officinalis, semen cuscutae, radix morindae officinalis, fructus rubi, rhizoma dioscoreae and folium mori. The invention further provides application of the traditional Chinese medicine composition in repairing and / or activating the residual ovarian function of the senescent ovary and improving the quality of the senescent oocyte, the traditional Chinese medicine composition can increase the volume and weight of the senescent ovary, increase the number of follicles of all levels in the senescent ovary, reduce apoptosis of granular cells in the ovary and improve the survival rate of the senescent ovary. The abnormal rate of oocytes, oxidative stress of the oocytes and DNA damage are reduced, development and maturation of residual follicles are promoted and maintained, and the traditional Chinese medicine composition has a wide application prospect.

The invention discloses a nerve cell senescence resisting medicine containing p-hydroxybenzaldehyde and application thereof.The p-hydroxybenzaldehyde is adopted as the only active substance, and the p-hydroxybenzaldehyde can reduce accumulation of DNA damage in cells, reduce activity of beta-galactosidase in the cells and slow down reduction of cell metabolic capacity, so that the nerve cell senescence resisting medicine is obtained. Therefore, the senescence of nerve cells is effectively slowed down, the cognitive function is improved, and a potential treatment effect is achieved in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

The invention discloses lactobacillus crispatus for relieving senescence by promoting collagen synthesis and a metagen of the lactobacillus crispatus, and belongs to the technical field of microorganisms and medicines. The lactobacillus crispatus CCFM1462 metagen provided by the invention has a good skin anti-aging effect, the content of collagen is increased, meanwhile, the skin moisture can be increased, and the skin oxidation resistance can be improved. Specifically, the enzyme activity of MMP-3 and MMP-1 of HSF cells can be inhibited in vitro by thallus lysate, and the content of COL I and COL III and the enzyme activity of LH1 can be improved in vitro from fermentation of supernate; the enzyme activity of MMP-1 and MMP-3 can be inhibited by orally taking inactivated thalli; the self-fermented supernate is orally taken, so that the enzyme activity of LH1 and LOX can be improved, the enzyme activity of MMP-3 can be reduced, and the anabolism of collagen can be regulated and controlled.

The invention discloses a circRNA nano delivery system capable of reversing nucleus pulposus progenitor cell senescence and a preparation method and application of the circRNA nano delivery system. The circRNA nano delivery system comprises: a) Klotho circRNA, and b) a liposome, and the liposome comprises a vascular peptide vasculotide, an ionizable lipid molecule, a phospholipid, a PEG lipid, and a steroid. The invention also provides application of the circRNA nano delivery system capable of reversing nucleus pulposus progenitor cell senescence in preparation of drugs for treating intervertebral disc degeneration. The invention provides liposome particles (Vas-Klotho-LNP) which have targeted NPPCs and wrap circRNA, Klotho circRNA is efficiently introduced into the NPPCs through Tie2 agonist peptide, so that rejuvenation of the NPPCs is promoted, ECM synthesis is promoted, and regeneration and repair of intervertebral discs are synergistically promoted in vivo and in vitro.

The invention belongs to the technical field of biology, and discloses a fusion type polypeptide for improving the activity of umbilical cord mesenchymal stem cells and application of the fusion type polypeptide. The amino acid sequence of the fusion type polypeptide provided by the invention is any one sequence as shown in SEQ ID NO.1-3. The fusion type polypeptide is obtained by integrating an extracellular matrix amino acid sequence and a heparin amino acid sequence. The umbilical cord mesenchymal stem cells obtained by culturing the fusion type polypeptide have good multiplication capacity, can promote expression of the Ki67 gene and inhibit aging of the umbilical cord mesenchymal stem cells, and have wide application prospects.

A composition capable of preventing or improving skin aging by controlling a senescence biomarker of melanocytes is disclosed. The composition includes a thymol ester-based compound as an effective ingredient, whereby when applied to a subject in which skin cells are flattened or enlarged, or β-galactosidase of melanocytes is activated, it can exhibit the effect of preventing or improving skin aging.

The invention relates to the technical field of traditional Chinese medicines, and particularly discloses an anti-aging and anti-fatigue traditional Chinese medicine formula and a preparation method thereof. The traditional Chinese medicine formula comprises the following raw materials in parts by weight: 10-12 parts of ginseng, 10-15 parts of rhodiola rosea, 8-10 parts of dendrobium officinale, 5-6 parts of turmeric, 5-8 parts of cordyceps militaris, 8-10 parts of radix puerariae, 6-10 parts of schisandra chinensis, 1-3 parts of liquorice, 8-10 parts of lycium ruthenicum, 8-10 parts of cistanche, 10-12 parts of acanthopanax and 8-10 parts of phellinus igniarius. The adaptive capacity of an organism to an anoxic environment is improved, fatigue is effectively relieved, and various active ingredients contained in the health-care food contribute to delaying the senescence process.

The present invention discloses the application of MY-1B in the preparation of drugs for improving ovarian senescence, belonging to the technical field of biomedicine, aiming to solve the problem of how to effectively delay ovarian senescence and improve ovarian function. Experiments have proved that during ovarian senescence, the mRNA m<supgt;5< / supgt;C modification level and the expression level of methyltransferase in ovarian granulosa cells increase. Supplementation with MY-1B can improve the condition caused by mRNA m Nsun2 expression.

The invention belongs to the technical field of biological medicines, and particularly relates to a recombinant polypeptide for improving the activity of bone marrow mesenchymal stem cells and application of the recombinant polypeptide. The amino acid sequence of the recombinant polypeptide is as shown in SEQ ID NO.3. The recombinant polypeptide is obtained by integrating an extracellular matrix amino acid sequence and a heparin amino acid sequence. The recombinant polypeptide provided by the invention can promote the expression of the Ki67 gene and improve the proliferative activity of the bone marrow mesenchymal stem cells, also has the effect of inhibiting the replicative aging of the bone marrow mesenchymal stem cells, and has a wide application prospect.

The invention discloses a Bifidobacterium bifidum CCFM1424 capable of relieving senescence and an application of the Bifidobacterium bifidum CCFM1424, and belongs to the technical field of microorganisms. The bifidobacterium bifidum CCFM1424 disclosed by the invention can be used for effectively relieving cognitive defects of aged mice, improving the oxidation resistance (SOD, CAT, MDA and GSH-Px) of the brain and the liver, reducing the levels of proinflammatory factors TNF-alpha, IL-1beta and IL-6 in serum and relieving colitis. In addition, the intervention of the bifidobacterium bifidum CCFM1424 can maintain muscle health, and can improve the change of intestinal flora and intestinal metabolites related to aging. According to the bifidobacterium bifidum, the application range of the bifidobacterium bifidum as probiotics is expanded, and the bifidobacterium bifidum has a huge application prospect in the aspect of relieving senescence.

The invention discloses application of salvianolic acid A in preparation of a medicine for preventing and treating vulnerable plaques of advanced atherosclerosis. The invention also discloses application of the salvianolic acid A combined with ferulic acid or the salt thereof in preparation of drugs for preventing and treating advanced atherosclerosis vulnerable plaques. Researches find that salvianolic acid A can promote apoptosis of senescent vascular smooth muscle cells and has a Senlytics effect; the salvianolic acid A stabilizes vulnerable atherosclerotic plaques by reducing the load of senescent vascular smooth muscle cells; the salvianolic acid A is in non-covalent binding with ASP54, ALA55, LYS58, ASP93, ASP102 and LYS112 of the HSP90AA1 to play a role in inhibition, and the ASP93 has the greatest contribution to binding free energy. The research of the invention is of great significance to the development and application of drugs with anti-aging effect for stabilizing advanced atherosclerotic vulnerable plaques.

The invention relates to a phenylacetylglutamine / phenylacetylglycine induced vascular smooth muscle cell senescence model and an establishment method and application thereof, and belongs to the technical field of cell models.The method comprises the following steps that vascular smooth muscle cell suspension is placed in a porous plate, 10% of FBS and 1% of mycillin are added into a culture medium, 24 h after cells adhere to the wall, the vascular smooth muscle cell senescence model is obtained, and the vascular smooth muscle cell senescence model is obtained. The method comprises the following steps of: adding a proper amount of phenylacetyl glutamine or phenylacetyl glycine dimethyl sulfoxide solution into a porous plate, changing a serum-free culture medium, continuously culturing for 24 hours, adding a proper amount of phenylacetyl glutamine or phenylacetyl glycine dimethyl sulfoxide solution into the porous plate, changing the culture medium added with phenylacetyl glutamine or phenylacetyl glycine once every 24 hours, and collecting cells after 72 hours. According to the invention, phenylacetylglutamine / phenylacetylglycine is used for inducing and establishing the vascular smooth muscle cell senescence model for the first time, the method is easy to operate and low in cost, and a foundation is laid for researching the relationship between cardiovascular diseases and senescence.

The invention discloses an application of interaction of a pear transcription factor PbrDDI2 and a PbrAPX14 gene promoter in regulation and control of maturation and senescence of pear fruits. The nucleotide sequence of the pear transcription factor PbrDDI2 is as shown in SEQ ID NO.1 in a sequence table, and the amino acid sequence of the gene coded protein is as shown in SEQ ID NO.2. The invention discloses the transcription factor PbrDDI2 for regulating and controlling the PbrAPX14 gene expression of the pear fruit for the first time. The invention clarifies an action mechanism of interaction of cis-acting elements (TTTGTCG / CGACAAA) in PbrDDI2 and PbrAPX14 gene promoters in clearing endogenous H2O2 accumulation and further inhibiting synthesis of ethylene so as to inhibit fruit ripening and senescence, and provides a theoretical and practical basis for cultivating anti-senescence high-quality pear varieties.

Metastatic uveal melanomas are highly resistant to all existing treatments. To identify actionable vulnerabilities, the inventors conducted a CRISPR-Cas9 knockout screen using a library composed of chromatin remodelers. They revealed that the histone H3 methyltransferase SETDB1 plays a critical role in metastatic uveal melanoma cell proliferation and survival. Functionally, SETDB1 knockdown triggers decreased expression of genes related to replication and cell cycle and promotes growth arrest associated with increased markers for DNA damage and senescence entry. Using pre-clinical model, they further demonstrated that anti-SETDB1 therapy tumor growth in vivo. The inventors identify SETDB1 as a new relevant therapeutic target for the treatment of metastatic uveal melanomas. The present invention relates to a method for treating uveal melanoma in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of SETDB1 inhibitor.

The invention relates to a collagen peptide composition and application thereof in recovering or promoting collagen content. The collagen peptide composition comprises Galvor E and a collagen peptide. Specifically, the collagen peptide composition further comprises at least one of aronia melanocarpa fruit concentrated solution and EGCG (epigallocatechin gallate). Compared with a single drug, the collagen peptide composition can more effectively recover the content of various collagens in skin cells, and also reduces the expression of senescence genes, so that the skin elasticity is recovered, and the skin elasticity is improved. The senescence is delayed.

The invention discloses a method for extracting an anti-aging component camellia saponin A from camellia on the basis of a full-bionic targeted extraction technology and application of the anti-aging component camellia saponin A. Efficient enrichment and structure protection of the camellia saponin A are achieved by simulating the whole process of decomposition and absorption of the oral cavity, the stomach and the intestinal tract of a human body. Specifically, the camellia flowers or leaves are pretreated through supercritical extraction, lipid and gel impurities which are contained in the camellia flowers or leaves and are prone to forming gelatinoids are removed, and convenience is provided for subsequent purification; the problems that the camellia saponin A is low in yield and easy to degrade are solved by applying a full-bionic enzymolysis technology, and meanwhile, impurities such as lipid, protein, tannin and sugar can be degraded through full-bionic extraction, so that convenience is provided for subsequent crystallization; and purifying by adopting a macroporous resin adsorption technology, and finally purifying by crystallization. The camellia saponin A obtained by the invention can better achieve the effects of improving wrinkles, repairing skin, brightening skin color and delaying senescence through multi-way and multi-azimuth anti-wrinkle, repairing and whitening effects, and can be widely applied to various types of cosmetics.

The invention discloses a bean dreg solid state fermentation preparation and application thereof in treating or preventing sarcopenia, and relates to the field of bean dreg processing, the bean dreg solid state fermentation preparation is obtained by taking lactobacillus paracasei LMX1 and pediococcus acidilactici IFJ1 as fermentation strains, taking bean dregs as a fermentation substrate, firstly performing solid state fermentation and then performing extraction. A myotubular atrophy model is established by inducing mouse myoblast C2C12 injury with TNF-alpha in vitro, the effect of the bean dreg solid-state fermentation preparation on C2C12 cells is explored, the influence of the bean dreg solid-state fermentation preparation on LPS-induced muscular atrophy mice is researched in vivo, and the result shows that the bean dreg solid-state fermentation preparation has potential effects of delaying senescence, promoting growth of muscular atrophy, preventing and treating muscular atrophy. The composition has the effects of preventing muscle atrophy and weakness related to aging and treating sarcopenia, and reference is provided for exploring potential application of plant active ingredients in the aspect of preventing or treating muscle functions.

The invention discloses application of lactobacillus rhamnosus to preparation of a product for improving and treating cognitive impairment. The invention discloses the new application of the rhamnosus cheese for the first time, and the rhamnosus cheese can improve or treat cognitive impairment related to aging by improving behavioral function change, brain inflammatory factors, oxidative stress activity and neurotransmitter level caused by aging of mice and regulating transcriptome, intestinal microbiome, metabolome and the like. The lactobacillus rhamnosus has a potential application prospect in the aspect of improving learning and memory ability impairment caused by senescence.

The invention belongs to the technical field of biological medicines, and discloses a B cell and cartilage cell senescence targeting osteoarthritis treatment medicine. The invention provides an application of an anti-MIF antibody or an antigen binding fragment thereof as a B cell targeting immunomodulator in osteoarthritis treatment drugs, the anti-MIF antibody or the antigen binding fragment thereof regulates and controls an MIF / HMGB1 / MMP13 signal axis through a neutralization effect with MIF, so that the MIF and B cells are significantly co-localized, expression of HMGB1 in the B cells is promoted, and the osteoarthritis treatment effect is improved. The senescence of B cells is reduced and the B cells are promoted to regulate or repair phenotype transformation so as to destroy chronic inflammatory circulation and diffusion of pathogenic plasma cells, and the expression of MMP13 in joint tissues is reduced so as to maintain the steady state of cartilage tissues; the preparation method has an excellent application prospect in preparation of an OA intra-articular injection drug which realizes rapid anti-inflammatory and long-term cartilage protection effects and can realize a lasting curative effect through low-frequency drug delivery.

The invention relates to a calcium homeostasis disruptor in combination with a selective Death Receptor 5 (DR5) agonist for use in a method of treating a patient suffering from a tumour. The invention further relates to a pharmaceutical composition, comprising a calcium homeostasis disruptor in combination with a selective Death Receptor 5 (DR5) agonist and, optionally, an inducer of senescence. The invention further relates to methods of treating a patient having a tumour, and to a calcium homeostasis disruptor in combination with a selective DR5 agonist, for use in a method of selectively killing senescent cells, including senescent cancer cells.

The invention relates to health-preserving conditioning tea and a preparation method thereof, and belongs to the technical field of tea drinks, and the health-preserving conditioning tea comprises a paederia scandens extract, a radix fici simplicissimae extract, a Chinese yam-eclipta alba distilled liquid medicine and an angelica sinensis extract. The prepared health-preserving conditioning tea can help human body aging. Meanwhile, ovarian senescence can be delayed, and the ovarian health state can be improved.

The invention belongs to the technical field of medicine research, and particularly relates to application of eicosapentaenoic acid in preparation of a medicine for preventing and treating myocardial cell death and senescence induced by adriamycin. Experiments prove that a low dose (15 [mu] M) of eicosapentaenoic acid (EPA) has no obvious toxicity to H9C2 myocardial cells, and the low dose (15 [mu] M) of EPA can improve the death phenomenon of the H9C2 myocardial cells caused by adriamycin; the EPA can be used for reducing the increase of the content of beta-galactosidase in adriamycin-induced H9C2 cells. P53 and P21 related to aging are highly expressed after being treated by 0.5 uM DOX of H9C2 myocardial cells, and EPA can obviously reduce the expression of the P53 and P21. After DOX treatment, the expression of core proteins G3BP1G3BP1 and UBAP2L of stress particles in the H9C2 myocardial cells is increased, and the phenomenon can be improved by EPA (eicosapentaenoic acid). The experiments prove that eicosapentaenoic acid can improve death and aging of adriamycin-induced H9C2 myocardial cells.